$22.92
6.60% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US34962G1094
Symbol
FBRX
Sector
Industry

Forte Biosciences Inc Stock price

$22.92
+3.13 15.82% 1M
+9.22 67.30% 6M
+2.38 11.57% YTD
+4.65 25.42% 1Y
-31.08 57.56% 3Y
-168.78 88.04% 5Y
-4,645.83 99.51% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+1.42 6.60%
ISIN
US34962G1094
Symbol
FBRX
Sector
Industry

Key metrics

Market capitalization $33.51m
Enterprise Value $17.15m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.57
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-35.63m
Free Cash Flow (TTM) Free Cash Flow $-29.73m
Cash position $16.36m
EPS (TTM) EPS $-19.39
Short interest 0.07%
Show more

Is Forte Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Forte Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Forte Biosciences Inc forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Forte Biosciences Inc forecast:

Buy
100%

Financial data from Forte Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.04 0.04
-
-
-0.04 -0.04
-
-
- Selling and Administrative Expenses 16 16
56% 56%
-
- Research and Development Expense 20 20
6% 6%
-
-36 -36
15% 15%
-
- Depreciation and Amortization 0.04 0.04
-
-
EBIT (Operating Income) EBIT -36 -36
15% 15%
-
Net Profit -34 -34
12% 12%
-

In millions USD.

Don't miss a Thing! We will send you all news about Forte Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Forte Biosciences Inc Stock News

Neutral
Business Wire
about one month ago
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will host an R&D Day on December 3, 2024 at 4:30 p.m. ET. The R&D Day will focus on the development of FB102 across autoimmune indications and will feature key thought leaders in celiac disease,...
Neutral
Business Wire
about one month ago
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced an oversubscribed $53 million equity financing to support the continuing clinical advancement of FB102. “We are appreciative of the support from new and existing investors including OrbiMed, Janus ...
Neutral
Business Wire
about one month ago
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced third quarter 2024 results and provided a business update. Third Quarter 2024 Business Highlights “We continue to make excellent progress with FB102 and have begun dosing patients in a celiac disea...

Company Profile

Forte Biosciences, Inc. engages in the development of biopharmaceutical products. It is a clinical stage dermatology company focuses in the treatment of inflammatory skin diseases. It offers FB-401, a live bio-therapeutic product. The company was founded by Paul A. Wagner in 2017 and is headquartered in Torrance, CA.

Head office United States
CEO Paul Wagner
Employees 9
Founded 2017
Website www.fortebiorx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today